Pancreatic Cancer Research

ResearcherBeckman Research InstituteActive in the last 2 years

Tsutomu Fujii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0625-1911; OpenAlex author ID A5047606517, A5057898224. Sources: OpenAlex.

Their work

Papers
96 (first author 27, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
276
Papers, trials and grants by year

2011: 5 papers · 2012: none · 2013: 4 papers · 2014: 4 papers · 2015: 3 papers · 2016: 5 papers · 2017: 4 papers · 2018: 7 papers · 2019: 6 papers · 2020: 9 papers · 2021: 7 papers · 2022: 7 papers · 2023: 9 papers · 2024: 2 papers · 2025: 17 papers · 2026: 7 papers

Papers 50 of 96

  1. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Co-author DOI 10.1002/ijc.70801↗
  2. Development of novel serum peptide biomarkers for screening pancreatic cancer. Last author DOI 10.1007/s00535-025-02314-z↗
  3. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  4. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  5. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  6. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  7. Aporphine Alkaloid N-Nornuciferine from Nelumbo nucifera Induces MAPK-Associated Autophagy Under Nutrient Deprivation in Human Pancreatic Cancer Cells. Co-author DOI 10.3390/ph19091454↗
  8. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  9. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  10. Clinical Impact for Prognostic Index of Nodal Stations and Reconsideration of Optimal Regional Lymph Node Station in Pancreatic Cancer. First author DOI 10.1002/jhbp.12179↗
  11. Long-term outcomes of prophylactic right-half dissection of the superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic ductal adenocar… Last author DOI 10.1007/s00595-025-03062-6↗
  12. Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis who were treated with chemotherapy involv… Last author DOI 10.1007/s12328-025-02175-2↗
  13. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  14. Toyaburgine, a Synthetic N-Biphenyl-Dihydroisoquinoline Inspired by Related N,C-Coupled Naphthylisoquinoline Alkaloids, with High In Vivo Efficacy in Preclinic… Co-author DOI 10.1021/acschembio.4c00870↗
  15. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Co-author DOI 10.1093/bjs/znaf049↗
  16. Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. Last author DOI 10.1097/mpa.0000000000002441↗
  17. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  18. [Recent trends in multidisciplinary treatment for pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.122.803↗
  19. Grandifloridin D: A Potent Antiausterity Agent Targeting Pancreatic Cancer Cells via Akt/mTOR and Autophagy Inhibition. Co-author DOI 10.1248/bpb.b25-00545↗
  20. A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Tri… Last author DOI 10.1371/journal.pone.0325667↗
  21. Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery. Last author DOI 10.21873/anticanres.17618↗
  22. Novel CTC Detection Method in Patients with Pancreatic Cancer Using High-Resolution Image Scanning. Last author DOI 10.3390/cancers17223640↗
  23. McKeown Esophagectomy for Esophageal Cancer Following Pancreaticoduodenectomy Using a Mesenteric Approach for Pancreatic Cancer: A Case Report. Last author DOI 10.70352/scrj.cr.25-0204↗
  24. [Conversion Surgery for Pancreatic Cancer]. Last author PMID 39957218↗
  25. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peri… Last author DOI 10.1002/ags3.12719↗
  26. Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro, and In Vivo Evaluations. Co-author DOI 10.1021/acs.jmedchem.4c01141↗
  27. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreati… Last author DOI 10.1002/ags3.12613↗
  28. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  29. Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytolog… Last author DOI 10.1002/jhbp.1356↗
  30. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  31. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  32. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  33. Targeting Pancreatic Cancer with Novel Plumbagin Derivatives: Design, Synthesis, Molecular Mechanism, In Vitro and In Vivo Evaluation. Co-author DOI 10.1021/acs.jmedchem.3c00394↗
  34. Nicolaioidesin C: An Antiausterity Agent Shows Promising Antitumor Activity in a Pancreatic Cancer Xenograft Mouse Model. Co-author DOI 10.1021/acs.jnatprod.3c00019↗
  35. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  36. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  37. Abietane diterpenes from Abies spectabilis and their anti-pancreatic cancer activity against the MIA PaCa-2 cell line. Co-author DOI 10.1016/j.bmcl.2022.128723↗
  38. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  39. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
  40. Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1111/pin.13198↗
  41. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  42. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… First author DOI 10.1186/s13063-022-06049-7↗
  43. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00595-020-02220-2↗
  44. Author response to: Comment on: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. First author DOI 10.1093/bjs/znaa033↗
  45. Author's reply: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis (Br J Surg 2020; 107: 1811-1… First author DOI 10.1093/bjs/znab054↗
  46. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Co-author DOI 10.1097/mpa.0000000000001712↗
  47. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … Co-author DOI 10.1097/sla.0000000000003487↗
  48. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-020-08990-w↗
  49. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. First author DOI 10.21037/jgo-20-243↗
  50. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. First author DOI 10.1002/bjs.11792↗

Closest collaborators

The 25 strongest of 276 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suguru Yamada · 51 shared papers, 2011–2025 · strength 4.40
  2. Yasuhiro Kodera · 49 shared papers, 2011–2025 · strength 3.87
  3. Sohei Satoi · 26 shared papers, 2016–2026 · strength 3.61
  4. Masamichi Hayashi · 28 shared papers, 2011–2026 · strength 2.92
  5. Nana Kimura · 12 shared papers, 2020–2025 · strength 2.67
  6. Mitsuro Kanda · 30 shared papers, 2011–2026 · strength 2.05
  7. Mina Fukasawa · 9 shared papers, 2023–2025 · strength 1.94
  8. Katsuhisa Hirano · 9 shared papers, 2020–2025 · strength 1.83
  9. Michiaki Unno · 13 shared papers, 2016–2026 · strength 1.83
  10. Fuminori Sonohara · 17 shared papers, 2018–2022 · strength 1.62
  11. Suresh Awale · 7 shared papers, 2022–2026 · strength 1.53
  12. Haruyoshi Tanaka · 7 shared papers, 2023–2026 · strength 1.38
  13. Juthamart Maneenet · 6 shared papers, 2022–2026 · strength 1.35
  14. Daisuke Hashimoto · 9 shared papers, 2021–2026 · strength 1.33
  15. Tomohisa Yamamoto · 11 shared papers, 2017–2025 · strength 1.29
  16. Satoshi Hirano · 9 shared papers, 2020–2026 · strength 1.25
  17. Masayuki Sho · 9 shared papers, 2018–2026 · strength 1.25
  18. Yoshifumi Takeyama · 7 shared papers, 2023–2026 · strength 1.15
  19. Ippei Matsumoto · 7 shared papers, 2018–2026 · strength 1.11
  20. Masaya Suenaga · 12 shared papers, 2014–2025 · strength 1.05
  21. Hiroki Yamaue · 11 shared papers, 2016–2025 · strength 1.04
  22. So Yamaki · 7 shared papers, 2020–2025 · strength 0.97
  23. Nguyễn Duy Phan · 5 shared papers, 2022–2025 · strength 0.94
  24. Yuichi Nagakawa · 7 shared papers, 2018–2026 · strength 0.94
  25. Yoshihiro Shirai · 4 shared papers, 2025 · strength 0.93

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.